About 30 percent of melanoma patients with metastatic disease benefit from immunotherapy. At the same time, this means that 70 percent of all melanoma patients still lack effective treatment options. Göran Jönsson and his colleagues want to identify new medications for this patient group.
“It’s a fantastically prestigious grant, and we’re delighted to receive it. This means that together with my co-applicants, Kristian Pietras and Joan Yuan, I now have the time and resources to ask important questions about immunotherapy, tertiary lymphoid structures and melanoma disease. We have many ideas and thoughts on which we can now build, in order to understand the basic mechanisms behind why not all melanoma patients benefit from immunotherapy,” says Göran Jönsson, Professor of Molecular Oncology at the Faculty of Medicine’s Department of Clinical Sciences in Lund.
Three more researchers at Lund University received project grants from the Knut and Alice Wallenberg Foundation: Mikael Akke, Sara Linse and Michel Gisselbrecht at the Faculty of Science and LTH. Read more here: Four Lund researchers receive SEK 120 million from the Wallenberg Foundation
Read the press release from the Knut and Alice Wallenberg Foundation 23 research projects receive SEK 700 million in grants